摘要
背景:慢性肾脏疾病(CKD)仍然是公共卫生系统面临的重大挑战,它与用细胞外基质蛋白(如colo)替代肾功能组织相对应。泻湖和纤维连接蛋白。除肾保护策略外,目前还没有有效治疗CKD的方法。大麻素系统,更具体地说,大麻素受体1(CB1)和2(CB2)mAY是CKD治疗的新靶点。 方法:我们使用“大麻素受体”与“肾脏”、“肾病”、“糖尿病”、“肾纤维化”或“细胞途径”相结合的术语进行PubMed搜索。各种组合。我们分析了全文英语论文.。我们还查阅了已查明的文章的参考清单,以寻找进一步的相关文件。 结果:我们收集了正常肾生理和各种实验性肾病,尤其是糖尿病患者对大麻素系统的了解情况。我们还审查了在糖尿病和肥胖模型以及非代谢肾纤维化模型中,当使用CB1阻滞剂和/或CB2激动剂时获得的数据。我们还发现很少有数据可用,所以远距离细胞通路涉及大麻素受体下游在肾纤维化的发展过程中。 结论:大麻素受体在肾脏疾病和纤维化的发生发展中具有重要作用,尤其是CKD和糖尿病。
关键词: 大麻素受体,肾纤维化,糖尿病,慢性肾脏疾病,类内酰胺酶,肾生理学。
Current Medicinal Chemistry
Title:The Role of Cannabinoid Receptors in Renal Diseases
Volume: 25 Issue: 7
关键词: 大麻素受体,肾纤维化,糖尿病,慢性肾脏疾病,类内酰胺酶,肾生理学。
摘要: Background: Chronic kidney disease (CKD) remains a major challenge for Public Health systems and corresponds to the replacement of renal functional tissue by extra-cellular matrix proteins such as collagens and fibronectin. There is no efficient treatment to date for CKD except nephroprotective strategies. The cannabinoid system and more specifically the cannabinoid receptors 1 (CB1) and 2 (CB2) may represent a new therapeutic target in CKD.
Methods: We performed PubMed searches using the terms “cannabinoid receptors” in combination with “kidney” or ”renal disease” or “nephropathy” or “diabetes” or ”renal fibrosis” or ”cellular pathways” in various combinations. We analyzed full-text English-language papers. We also searched the reference lists of identified articles for further relevant papers.
Results: We gathered data regarding the current state of knowledge on the cannabinoid system in normal renal physiology and in various experimental nephropathies, especially diabetes. We also reviewed data obtained in models of diabetes and obesity as well as in non metabolic models of renal fibrosis when CB1 blockers and/or CB2 agonists were used. We also found that very few data are available so far regarding the cellular pathways involved downstream of the cannabinoid receptors in the development of renal fibrosis.
Conclusion: Overall, we found that the cannabinoid receptors are a promising target in the development of renal disease and fibrosis, particularly in CKD and diabetes.
Export Options
About this article
Cite this article as:
The Role of Cannabinoid Receptors in Renal Diseases, Current Medicinal Chemistry 2018; 25 (7) . https://dx.doi.org/10.2174/0929867324666170911170020
DOI https://dx.doi.org/10.2174/0929867324666170911170020 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Interventions for Diabetic Neuropathy & Nephropathy: A Review
Current Psychopharmacology <i>Coccidioidomycosis</i> Resulting in a Prosthetic Joint Infection in an Immunocompetent Patient after a Total Hip Arthroplasty: A Case Report and Review of the Literature
Infectious Disorders - Drug Targets New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine
Current Pharmacogenomics and Personalized Medicine Exosomes: A Role for Naturally Occurring Nanovesicles in Cancer Growth, Diagnosis and Treatment
Current Gene Therapy Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters Endothelial Dysfunction in Renal Failure: Current Update
Current Medicinal Chemistry Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Angiotensin (1-7) and other Angiotensin Peptides
Current Pharmaceutical Design Glucose and LDL Lowering: The Need for Intensive Therapy
Current Vascular Pharmacology Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Natural Medicine:The Genus Angelica
Current Medicinal Chemistry Mineralocorticoid Receptor-Associated Hypertension and Target Organ Damage: Clinical Relevance for Resistant Hypertension in End Stage Renal Disease
Current Hypertension Reviews Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Is Atherothromboaspiration a Possible Solution for the Prevention of No-Reflow Phenomenon in Acute Coronary Syndromes? Single Centre Experience and Review of the Literature
Current Vascular Pharmacology Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression
Current Vascular Pharmacology Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases
Recent Patents on Inflammation & Allergy Drug Discovery